Partners with Leading West Coast Distributor to Broaden Reach into Food Processors
SAN DIEGO (June 16, 2016) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that it has initiated operational testing of PURE® Hard Surface disinfectant with a leading Quick Service Restaurant (QSR) chain and a leading casual dining chain. In addition, the Company announced that it had entered into a distribution agreement with a leading West Coast specialty chemical distributor to food processors.
The two national restaurant chains are conducting multi-store operational testing over the next few weeks, in order to establish appropriate protocols, with the expectation of following this with US system wide roll outs. In both cases, PURE Hard Surface will be used extensively throughout the stores on multiple food contact surfaces, as well as other surfaces susceptible to Norovirus contamination.
PURE Hard Surface will replace less effective, toxic legacy products, and provide uniquely effective Norovirus elimination.
PURE’s powerful SDC antimicrobial is distinguished as a non-toxic and fast acting eliminator of microorganisms in restaurant operations - increasing consumer and environmental safety. Use of PURE Hard Surface also delivers the dual advantages of providing brand protection for the user while strengthening risk management and preventive controls.
PURE Hard Surface is currently in use in SUBWAY® Restaurants, the largest QSR chain, and is being used by another QSR chain specifically to eliminate and prevent Norovirus. Four additional restaurant chains are in the midst of the product evaluation process.
PURE’s strategy to accelerate adoption of PURE Hard Surface and broaden reach among food processors includes selectively partnering with leading providers of specialty cleaning and sanitizing chemicals and technical services. Entering into a distribution agreement with a leading West Coast distributor provides access to their 40 person sales and technical service team and 1600 customer base. Many of their customers are concentrated in the produce, poultry and dairy industry segments, and represent excellent targets for PURE’s SDC technology.
This is the third distribution partnership that PURE has entered into.
* SUBWAY® is a registered trademark of Doctor's Associates Inc.
Hank R. Lambert, Chief Executive Officer, said that, “With foodborne illness so prominent in the media, and restaurants being the most frequent source of foodborne illness outbreaks, we continue to build awareness for PURE as a brand protection solution in the food industry by delivering a green antimicrobial technology. We are proud to play an important role in eliminating dangerous foodborne pathogens such as Norovirus with proactive restaurant chains.
“Expanding food processing market awareness of our unique and powerful food safety solution is key to our success. Importantly, with our recent FDA approvals for use of SDC as a direct food contact processing aid for fresh produce and raw poultry, the access to poultry and produce processors that our new West Coast distributor partner provides will be impactful.”
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry and raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2015, its Form 10-Q for the first quarter ended October 31, 2015 and its Form 10-Q for the second quarter ended January 31, 2016, and its Form 10- Q for the third quarter ended April 30, 2016. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Hank Lambert, CEO Terri MacInnis, VP of IR Tom Hemingway
PURE Bioscience, Inc. Bibicoff + MacInnis, Inc. Redwood Investment Group
619-596-8600 ext.103 818-379-8500 714-978-4425